Spots Global Cancer Trial Database for A Trial of PDL192 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial of PDL192 in Subjects With Advanced Solid Tumors
Official Title: A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors
Study ID: NCT00738764
Conditions
Interventions
Study Description
Brief Summary: This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
Detailed Description: The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 53365, Scottsdale, Arizona, United States
Site Reference ID/Investigator# 53364, Aurora, Colorado, United States
Contact Details
Name: Mihail Obrocea, MD
Affiliation: Abbott Biotherapeutics Corp.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
